ORIGINAL ARTICLE Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group Fabio Efficace & Massimo Breccia & Susanne Saussele & Ute Kossak-Roth & Annarita Cardoni & Giovanni Caocci & Weichu Chie & Adel Naeem & Ourania Nicolatou-Galitis & Kim Cocks & Marco Vignetti & Michele Baccarani & Franco Mandelli & Mirjam Sprangers Received: 24 February 2012 / Accepted: 20 March 2012 / Published online: 29 April 2012 # Springer-Verlag 2012 Abstract The objective of this study was to investigate the health-related quality of life (HRQOL) aspects valued the most by patients with chronic myeloid leukemia (CML) receiving targeted therapies (TT), and to compare their perception with that of health-care professionals’ (HCPs). Semi-structured interviews were conducted with 137 CML patients receiving TT from five different countries. An ad- ditional sample of 99 CML patients, completing an online interview, was considered for supportive analyses. A sample of 59 HCPs from 12 countries also participated in the study. Electronic supplementary material The online version of this article (doi:10.1007/s00277-012-1458-6) contains supplementary material, which is available to authorized users. F. Efficace (*) : A. Cardoni : M. Vignetti : F. Mandelli Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), GIMEMA Data Center, Via Benevento, 6, 00161 Rome, Italy e-mail: f.efficace@gimema.it M. Breccia Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy S. Saussele : U. Kossak-Roth Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany G. Caocci Department of Internistic Medical Sciences, University of Cagliari, Cagliari, Italy W. Chie Graduate Institute of Preventive Medicine and Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan A. Naeem Department of Hematology, University of Baghdad, Baghdad, Iraq O. Nicolatou-Galitis Dental Oncology Unit, Clinic of Hospital Dentistry, School of Dentistry, University of Athens, Athens, Greece K. Cocks York Trials Unit, University of York, York, UK M. Baccarani Department of Haematology and Oncology ‘L. e A. Seràgnoli’,St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy M. Sprangers Department of Medical Psychology, University of Amsterdam, Amsterdam, The Netherlands Ann Hematol (2012) 91:1371–1381 DOI 10.1007/s00277-012-1458-6